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Tuberculosis, which is caused by infection with Mycobacterium tuberculosis (Mtb), remains one of the major bacterial infections
worldwide. Host defense against Mtb is mediated by a combination of innate and adaptive immune responses. In the last 15
years, the mechanisms for activation of innate immunity have been elucidated. Toll-like receptors (TLRs) have been revealed to
be critical for the recognition of pathogenic microorganisms including mycobacteria. Subsequent studies further revealed that
NOD-like receptors and C-type lectin receptors are responsible for the TLR-independent recognition of mycobacteria. Several
molecules, such as active vitamin D3, secretary leukocyte protease inhibitor, and lipocalin 2, all of which are induced by TLR
stimulation, have been shown to direct innate immune responses to mycobacteria. In addition, Irgm1-dependent autophagy has
recently been demonstrated to eliminate intracellular mycobacteria. Thus, our understanding of the mechanisms for the innate
immune response to mycobacteria is developing.
1.Introduction
In humans, tuberculosis is one of deadly infectious diseases.
Indeed, approximately 2 million tuberculosis patients die
every year. The risk of disease is also increased by emergence
of acquired immune deﬁciency syndrome and development
of multidrug-resistant mycobacteria [1]. Therefore, it is
important to understand the host defense mechanisms
against mycobacteria. Inhalation of aerosols containing
Mycobacterium tuberculosis (Mtb) causes tuberculosis. After
inhalation, Mtb invades alveolar macrophages to enter into
the host and establish the infection. The host, in turn,
ignites defense responses through sequential activation of
immunity, a combination of innate and adaptive immune
systems. In the adaptive phase of immune responses, the
importance of Th1/IFN-γ-mediated responses in mycobac-
terial infection has been well established [2]. In contrast,
although macrophages are the major target of invasion
by Mtb, how the innate arm of immunity mediates host
defense against mycobacteria had long remained unknown.
However, the mechanisms behind innate immune responses
have been revealed in the past 15 years following the
identiﬁcation and characterization of pattern recognition
receptors (PRRs) such as Toll-like receptors (TLRs) [3].
Furthermore, it has been elucidated that TLR-dependent
activation of innate immunity controls the development of
adaptive immune responses [4]. The involvement of PRRs
other than TLRs in the recognition of mycobacteria has
also been revealed. In addition to the induction of adaptive
immune responses, the PRR recognition of mycobacteria
inducesexpressionofseveraleﬀectormoleculesparticipating
in the innate host responses. The role of these innate eﬀector
molecules in mycobacterial infection is being elucidated.
PRR-independent mechanisms for mycobacterial killing,
such as autophagy, have also been revealed. In this paper,
we will describe recent advances in our understanding of
eﬀectors that mediate innate immune responses against
mycobacteria.
2.Toll-Like Receptorsin
MycobacterialInfection
Innate immune responses after mycobacterial infection are
initiated by recognition of mycobacterial components by
PRRs, with mycobacterial components activating several2 Clinical and Developmental Immunology
TLRs (Figure 1). Genomic DNAfrom a Mycobacterium bovis
strain, bacillus Calmette–Gu´ erin (BCG), have an ability to
augment NK cell activity and induce type I IFNs from
murine spleen cells and human peripheral blood lympho-
cytes. The immunostimulatory activity of mycobacterial
DNA was ascribed to the presence of palindromic sequences
includingthe5-CG-3 motif, now called CpG motif [5],and
now known to activate TLR9 [6]. The mycobacterial cell wall
consists of several glycolipids. Among these, lipoarabino-
mannan (LAM) lacking mannose end capping, lipomannan
(LM), and phosphatidyl-myo-inositol mannoside (PIM) are
recognized by TLR2 [7, 8]. The 19-kDa lipoprotein of Mtb
also activates macrophages via TLR2 [9, 10]. TLR4 is also
presumed to recognize mycobacterial components.
The in vivo importance of the TLR-mediated signal in
host defense to Mtb was highlighted in studies using mice
lacking MyD88, a critical component of TLR signaling.
MyD88-deﬁcient mice are highly susceptible to airborne
infection with Mtb [11–13]. In contrast to mice lacking
MyD88, mice lacking individual TLRs are not dramatically
susceptibletoMtbinfection. SusceptibilityofTLR2-deﬁcient
mice to Mtb infection varies between diﬀerent studies [14,
15], while TLR4-deﬁcient mice do not show high suscep-
tibility to Mtb infection [16, 17]. A report demonstrates
that TLR9-deﬁcient mice are susceptible to Mtb infection
and mice lacking both TLR2 and TLR9 are more susceptible
[18]. These ﬁndings indicate that multiple TLRs might be
involved in mycobacterial recognition. However, a recent
report using mice lacking TLR2/TLR4/TLR9 indicated that
t h e s et r i p l eK Om i c es h o wam i l d e rp h e n o t y p et h a nM y D 8 8 -
deﬁcient mice [12]. Therefore, more intensive examination
is required to reveal whether TLRs or molecules other than
TLRs activating MyD88 mediate innate immune responses
to mycobacterial infection. This study also demonstrated
that Th1-like adaptive immune responses are induced even
in Mtb-infected MyD88-deﬁcient mice [12]. Therefore, the
TLR/MyD88-independent component of innate immunity is
involvedintheinductionofadaptiveimmuneresponsesdur-
ing mycobacterial infection. The TLR/MyD88-independent
response might be induced by other PRRs described below.
3.Non-TLRsinMycobacterialInfection
Several recent ﬁndings have indicated that PRRs other
than TLRs evoke innate immune responses [19]. These
include RIG-I-like receptors, NOD-like receptors (NLRs),
and C-type lectin receptors. Among these PRRs, NOD-like
receptors and C-type lectin receptors have been implicated
in the innate recognition of mycobacteria (Figure 2).
NOD2 is a member of NLRs that recognize muramyl
dipeptide (MDP), a core component of bacterial peptido-
glycan, in the cytoplasmic compartment. Macrophages from
NOD2-deﬁcient mice show a defective cytokine production
after Mtb infection [20]. Similarly, mononuclear cells of
individuals homozygous for the 3020insC NOD2 mutation
show a defective cytokine response after stimulation with
Mtb [7]. Activation of the NOD2-mediated pathway is
induced by stimulation with live Mtb, but not by heat-killed
Mtb [8]. Live Mtb, which is localized in the phagosomal
compartment within macrophages, stimulates the cytoso-
lic NOD2 pathway by inducing phagosomal membrane
damage [21]. The NOD2 ligand MDP is N-acetylated in
most bacteria. However, MDP is N-glycolylated by N-acetyl
muramic acid hydroxylase (NamH) in mycobacteria. Anal-
yses using M. smegmatis namH mutant and NOD2-deﬁcient
mice showed that N-glycolyl MDP is recognized by NOD2.
In addition, N-glycolyl MD Pi st h em o r ep o t e n tN O D 2
activator than N-acetyl MDP [22]. Thus, NOD2 contributed
to the recognition of mycobacteria.
Several members of the NLR family, such as NLRP1,
NLRP3, and IPAF, induce assembly of the inﬂammasome,
which leads to caspase-1-dependent secretion of IL-1β and
IL-18 [23]. The involvement of IL-1β and IL-18 in mycobac-
terial infection was demonstrated in studies using knockout
mice [24–27]. A recent study demonstrated that mycobac-
teria inhibit the inﬂammasome-dependent casapase-1 acti-
vation leading to defective IL-1β production [28]. The inhi-
bition of caspase-1 activation has further been shown to be
mediated by an Mtb gene, zmp1, which encodes a putative
Zn2+ metalloprotease. Thus, Mtb has a strategy that evades
the inﬂammasome-mediated innate immune responses.
C-type lectin receptors, such as mannose receptor, were
originally reported to mediate phagocytosis of mycobacteria
[29]. Another C-type lectin receptor, DC-SIGN, has been
shown to recognize mycobacteria, and thereby modulate the
function of dendritic cells [30–32]. Recognition of mycobac-
teria by dectin-1 has been shown to induce gene expression
such as TNF-α, IL-6, and IL-12 [33, 34]. In addition,
macrophage inducible C-type lectin (Mincle) has recently
been shown to recognize trehalose-6,6-dimycolate (TDM:
also called cord factor), a mycobacterial cell wall glycolipid
that is the most studied immunostimulatory component of
Mtb [35, 36], thereafter modulating macrophage activation.
Thus, several C-type lectin receptors are involved in the
recognition of mycobacteria.
CARD9 is involved in the signaling pathways of sev-
eral PRRs including TLRs, NOD-like receptors, and FcRγ-
associated C-type lectin receptors through association with
Bcl-10 and MALT. Therefore, it is not surprising that
CARD9-deﬁcient mice are highly susceptible to Mtb infec-
tion. However, interestingly the high susceptibility of
CARD9-deﬁcientmice to the infection has been shown to be
excessive inﬂammatory responses due to defective produc-
tion of the immunosuppressive cytokine IL-10 [37]. Mincle
is a member of C-type lectin receptors associated with
FcRγ [38]. Accordingly, TDM-induced immune responses
are mediated by the signaling pathway activating CARD9
[36, 39].
TLRs and C-type lectin receptors are expressed on the
plasma membrane or the endosomal/phagosomal mem-
brane, whereas NOD-like receptors are expressed within the
cytoplasm. Indeed, distinct patterns of TLR- and NOD-
like receptor-mediated gene expression proﬁles have been
demonstrated in infection with intracellular bacteria [40].
Thus, several PRRs recognize mycobacteria in distinct sites
within the host cells (macrophages) to synergistically induce
eﬀective host defense responses.Clinical and Developmental Immunology 3
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Figure 1: Recognition of mycobacteria by Toll-like receptors. TLR2 recognizes several mycobacterial-derived components.TLR9 recognizes
mycobacterial DNA including the CpG motif within endosomal compartments. TLR-dependent recognition of mycobacteria induces
activation of signaling pathways via the adaptor molecule MyD88, leading to activation of gene expression.
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Figure 2: Recognition of mycobacteria by pattern recognition receptors. Several pattern recognition receptors, such as NOD-like receptors
andC-type lectin receptors, mediate theTLR-independent recognitionofmycobacteria.NOD2,amemberofNOD-like receptors, recognizes
mycobacterial N-glycolyl MDP within the cytoplasm. DC-SIGN and dectin-1 are members of C-type lectin receptors, which are implicated
in the recognition of mycobacteria. In addition, Mincle has been shown to recognize TDM (a mycobacterial cell wall glycolipid).
4.EffectorsforMycobacterialKilling
The recognition of mycobacteria by several PRRs induces
the expression of several genes that mediate host defense
(Figure 3). Among these gene products, vitamin D receptor
(VDR) and Cyp27b1, a 25-hydroxyvitamin D3 1-α-hydrox-
ylase that catalyzes inactive provitamin D into the bioactive
form of vitamin D (1, 25 (OH)2D3), have been shown to
be induced by TLR2 ligands in human macrophages [41].
Stimulation of macrophages with 1, 25 (OH)2D3 induces
the expression of the antimicrobial peptide cathelicidin, and
thereby enhances the antimycobacterial killing activity [42].
In addition to cathelicidin, the small cationic antimicrobial
peptide defensin mediates innate immune responses to Mtb
[43, 44]. Experimental infection of the lung epithelial cell
line A549 with Mtb strongly induces production of human
β-defensin HBD-2, which leads to Mtb killing [43]. HBD-2
expression has also been shown to be induced by TLR2 [45].4 Clinical and Developmental Immunology
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Figure 3: TLR-dependent innate response to mycobacteria. Several TLR-dependent gene products mediate innate immune responses to
mycobacteria.Mycobacterial stimulationofTLR2induces expressionofCyp27b1 andvitaminD receptor (VDR),bothofwhichare involved
in vitamin D3-dependent induction ofcathelicidin which directly kills mycobacteria.TLR-dependent induction ofSLPImediates disruption
of the mycobacterial cell wall. Lcn2, which is also induced by TLR stimulation, is internalized into the alveolar epithelial cells and inhibits
mycobacterial growth by sequestering iron uptake.
Gene expression analyses of the lung of mycobacteria-
infected mice have identiﬁed several TLR-dependent genes
that are involved in innate immune responses during
mycobacterial infection. These genes include Slpi,e n c o d i n g
secretory leukocyte protease inhibitor (SLPI), and Lcn2,
encoding lipocalin 2 (Lcn2). SLPI is a secreted protein
composed of two cysteine-rich whey acidic protein (WAP)
domains [46–48]. SLPI was named after its presence in
secretionsanditsfunctionasaserineproteaseinhibitor.SLPI
was originally shown to mediate wound healing [49, 50].
SLPI is produced by bronchial and alveolar epithelial cells
as well as alveolar macrophages and is secreted into the
alveolar space at the early phase of mycobacterial respiratory
infections. Recombinant mouse SLPI eﬀectively inhibits the
in vitro growth of BCG and Mtb through disruption of the
mycobacterial cell wall structure. Cationic residues within
the WAP domains of SLPI are essential for the disruption
of mycobacterial cell walls. Moreover, SLPI-deﬁcient mice
are highly susceptible to mycobacterial infection [51]. The
mechanism by which SLPI attaches to the membrane of
mycobacteria has been elucidated. SLPI recognizes mannan-
capped lipoarabinomannans and phosphatidylinositol man-
noside, which are conserved in mycobacteria. Thus, SLPI
might act as a PRR in order to bind to the mycobacterial
membrane [52].
Lcn2 (also known as neutrophil gelatinase-associated
lipocalin, 24p3, or siderocalin) was originally identiﬁed in
the granules of human neutrophils. Lcn2 is a member of the
lipocalin protein family and able to bind to small hydropho-
bic molecules, siderophore. It is a bacterial molecule made
in iron-limited environment and facilitates iron uptake by
bacteria [53–58]. The expression of Lcn2 is increased in
macrophages of LPS-treated mice [59]. In addition, it is
secreted into the alveolar space by alveolar macrophages and
epithelialcellsduringtheearlyphaseofrespiratory mycobac-
terial infection. Lcn2 inhibits in vitro growth of Mtb by
binding the mycobacterial siderophore carboxymycobactin,
thereby sequestering iron uptake. Moreover, Lcn2-deﬁcient
mice are highly susceptible to intratracheal infection with
Mtb. Lcn2 is internalized into alveolar epithelial cells by
endocytosis and colocalized with mycobacteria within the
cells. Therefore, Lcn2 presumably sequesters iron uptake of
mycobacteria within epithelialcellsandtherebyinhibitstheir
intracellular growth. Within macrophages, the endocytosed
Lcn2 and mycobacteria show distinct patterns of subcellular
localization, which might allow growth of mycobacteria
within macrophages [60]. Thus, Lcn2, which is secreted into
the alveolar space during the early phase of mycobacterial
infection,isendocytosedintoalveolarepithelialcells,thereby
inhibiting mycobacterial growth [61].
5.AutophagyinMycobacterialInfection
Phagocytosis of myobacteria and PRR-dependent recog-
nition of mycobacteria activate several eﬀector functions
in macrophages (Figure 4). Maturation of phagosomes is
a crucial step in the elimination of intracellular bacte-
ria. The natural-resistance-associated macrophage protein
(Nramp1), which is encoded by Slc11a1, is thought to
mediate transportation of divalent cations in the phago-
somal membrane and thereby sequesters iron (Fe2+)f r o m
mycobacteria to enhance bacterial killing by macrophages
[62]. Polymorphisms of the SLC11A1 gene have been
associated with susceptibility to several infectious diseases,Clinical and Developmental Immunology 5
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Figure 4: Eﬀectors that mediate mycobacterial killing in macrophages. Macrophages eliminate invading mycobacteria by activating several
eﬀector functions, such as phagosomes and autophagy. Nramp1 is expressed in the phagosomal membrane and presumably mediates
mycobacterial killing by sequestering iron uptake. IFN-γ and the TLR4 ligand induce expression of LRG47, which in turn stimulates
autophagy in macrophages. Autophagy is responsible for mycobacterial killing by promoting fusion of mycobacterial phagosomes to
lysosomes.
including tuberculosis [63, 64]. However, in vivo studies
have shown that Nramp1-deﬁcient mice are not more
susceptible than wild-type mice to infection with virulent
Mtb [65]. Thus, the role of Nramp1 in mycobacterial in-
fection is still controversial. This might be due to the
presence of other killing mechanisms for mycobacteria in
macrophages. Indeed, autophagy has recently been shown
to be involved in host defense against several intracellular
pathogens that reside within phagosomes [66]. Autophagy
was originally identiﬁed as a homeostatic mechanism for
the catabolic reaction of cellular constitutes [67, 68]. It has
been demonstrated that autophagy mediates innate immune
responses against mycobacteria by promoting phagolysoso-
mal maturation within macrophages [69, 70]. Autophagy
is induced by IFN-γ-dependent induction of a member
of the immunity-related p47 guanosine triphosphatases
(IRG) family, LRG47 (also known as Irgm1) in murine
macrophages [69]. The importance of LRG47 in resistance
toMtbinfection wasdemonstrated inLRG47-deﬁcientmice,
which show high susceptibility to infection [71]. A subse-
quent study demonstrated that stimulation of macrophages
with the TLR4 ligand LPS leads to the MyD88-independent
induction of autophagy, which enhances mycobacterial
colocalization with the autophagosomes. Since LPS stim-
ulation induces expression of LRG47, the TLR signaling
establishes a close relationship between innate immunity
and autophagy in mycobacterial infection [72]. In humans,
the most equivalent gene to murine Irgm1 is IRGM. IRGM
has also been implicated in the induction of autophagy in
mycobacteria-infected human macrophages [73]. Irgm1 has
been shown to associate with the mycobacterial phagosome
by interacting with phosphatidylinositol-3,4-bisphosphate
(PtdIns(3,4)P(2)) and PtdIns(3,4,5)P(3) [74]. The connec-
tion of the IRG family of proteins with autophagy has been
further demonstrated in an alternative intracellular infection
model. In this study, Irgm3 (also known as IGTP) has been
implicated in autophagy induction in macrophages infected
with Toxoplasma gondii [75].
p62 (also called A170 or SQSTM1) directly binds to
cytosolic polyubiquitinated proteins and thereby induces
their autophagic clearance [76, 77]. It has also been shown
that p62 targets intracellular Salmonella typhimurium dec-
orated by ubiquitinated proteins to induce autophagy [78].
In the case of mycobacteria residing in the phagosome, p62
delivers cytosolic ubiquitinated proteins to autophagolyso-
somes where they are proteolytically processed to products
that are able to kill mycobacteria [79]. In accordance with
this ﬁnding, it has been shown that mycobacterial killing by
ubiquitin-derived peptides is enhanced by autophagy [80].
As described above, 1, 25 (OH)2D3 mediates antimy-
cobacterial activity via induction of cathelicidin. A recent
report demonstrated that 1, 25 (OH)2D3-mediated expres-
sion of cathelicidin induces autophagy [81]. Thus, several
innate immune eﬀectors are closely interacted.
6.Human GeneticsinTuberculosis
In addition to the intensive studies using murine models,
considerable advances have been made in our understanding
of the susceptibility to Mtb infection in humans through
the identiﬁcation of mutations and polymorphisms of6 Clinical and Developmental Immunology
innate immunity-related genes in tuberculosis patients. As
described above, polymorphisms of the SLC11A1 gene are
associated with tuberculosis. Subsequent studies identiﬁed
a signiﬁcant distinction between tuberculosis patients and
healthy controls in TLR2 Arg753Gln polymorphism geno-
type, indicating that the TLR2 polymorphism inﬂuences the
susceptibility of Mtb infection [82]. VDR polymorphisms
have also been implicated in the susceptibility of Mtb
infection[83].Thesestudiessuggestthatseveralgenes,which
havebeenrevealedtobecriticalin innate responses in mouse
models of Mtb infection, regulate Mtb infection in humans.
7.Conclusion
Since the discovery of TLRs at the end of the 20th century,
rapid advances have been made in our understanding
of the mechanisms for activation of innate immunity.
Accordingly, innate immunity has been revealed to have a
pivotal role in host defense against mycobacteria. The TLR-
independent mechanisms for the innate immune response
to mycobacteria have also been elucidated. The emergence
of multidrug-resistant Mtb is now a major public health
problem all over the world. In this context, it is highly
critical to develop a new strategy for the treatment of
Mtb-infected patients that supplements the conventional
antimycobacterial chemotherapeutic drugs. More precise
understanding of the innate immune response to Mtb will
pave the way for the development of an eﬀective drug
that targets the host innate immunity for the treatment of
tuberculosis.
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